Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Biosimilar Pharmaceuticals"" wg kryterium: Temat


Tytuł :
Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects.
Autorzy :
Zhang H; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Li C; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Liu J; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Wu M; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Li X; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Zhu X; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Li Q; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Wang B; Feiyang Biotechnology (Jilin) Co. Ltd ., China.
Mao Y; Feiyang Biotechnology (Jilin) Co. Ltd ., China.
Ding Y; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Jin Q; Department of Hepatology, The First Hospital of Jilin University , Jilin, China.
Pokaż więcej
Źródło :
Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2021 Feb; Vol. 30 (2), pp. 185-192. Date of Electronic Publication: 2020 Dec 22.
Typ publikacji :
Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms :
Biosimilar Pharmaceuticals/*pharmacokinetics
Bone Density Conservation Agents/*pharmacokinetics
Denosumab/*pharmacokinetics
Adult ; Biosimilar Pharmaceuticals/administration & dosage ; Biosimilar Pharmaceuticals/adverse effects ; Bone Density Conservation Agents/administration & dosage ; Bone Density Conservation Agents/adverse effects ; China ; Denosumab/administration & dosage ; Denosumab/adverse effects ; Double-Blind Method ; Female ; Healthy Volunteers ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Patient Safety ; Therapeutic Equivalency
Czasopismo naukowe
Tytuł :
Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
Autorzy :
Haifer C; St Vincent's Hospital Sydney, Sydney, NSW.; The University of Sydney, Sydney, NSW.
Srinivasan A; Eastern Health, Melbourne, VIC.; Monash University Eastern Health Clinical School, Melbourne, VIC.
An YK; Mater Hospital Brisbane, Brisbane, QLD.; The University of Queensland, Brisbane, QLD.
Picardo S; Royal Perth Hospital, Perth, WA.
van Langenberg D; Eastern Health, Melbourne, VIC.; Monash University Eastern Health Clinical School, Melbourne, VIC.
Menon S; Royal Perth Hospital, Perth, WA.
Begun J; Mater Hospital Brisbane, Brisbane, QLD.; Mater Research Institute, University of Queensland, Brisbane, QLD.
Ghaly S; St Vincent's Hospital Sydney, Sydney, NSW.; St Vincent's Clinical School, University of New South Wales, Sydney, NSW.
Thin L; Fiona Stanley Hospital, Perth, WA.; The University of Western Australia, Perth, WA.
Pokaż więcej
Źródło :
The Medical journal of Australia [Med J Aust] 2021 Feb; Vol. 214 (3), pp. 128-133. Date of Electronic Publication: 2020 Oct 17.
Typ publikacji :
Equivalence Trial; Journal Article; Multicenter Study
MeSH Terms :
Biosimilar Pharmaceuticals/*therapeutic use
Gastrointestinal Agents/*therapeutic use
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*therapeutic use
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Australia ; Biosimilar Pharmaceuticals/adverse effects ; Biosimilar Pharmaceuticals/economics ; Drug Costs ; Drug Substitution ; Female ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/economics ; Humans ; Infliximab/adverse effects ; Infliximab/economics ; Male ; Middle Aged ; Proportional Hazards Models ; Prospective Studies ; Severity of Illness Index ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
Autorzy :
Singh I; Intas Pharmaceuticals Ltd. (Biopharma), Plot No: 423/P/A, Sarkhej-Bavla Highway, Moraiya, Sanand, Ahmedabad, Gujarat, 382213, India.
Attrey A; Lambda Therapeutic Research Ltd., Lambda House, Plot No. 38, Survey No. 388, Near Silver Oak Club, S. G. Highway, Gota, Ahmedabad, Gujarat, 382481, India.
Garg A; Lambda Therapeutic Research Ltd., Lambda House, Plot No. 38, Survey No. 388, Near Silver Oak Club, S. G. Highway, Gota, Ahmedabad, Gujarat, 382481, India.
Patel R; Lambda Therapeutic Research Ltd., Lambda House, Plot No. 38, Survey No. 388, Near Silver Oak Club, S. G. Highway, Gota, Ahmedabad, Gujarat, 382481, India.
Jose V; Intas Pharmaceuticals Ltd. (Biopharma), Plot No: 423/P/A, Sarkhej-Bavla Highway, Moraiya, Sanand, Ahmedabad, Gujarat, 382213, India. .
Pokaż więcej
Źródło :
Clinical drug investigation [Clin Drug Investig] 2021 Jan; Vol. 41 (1), pp. 29-42. Date of Electronic Publication: 2020 Nov 24.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms :
Biosimilar Pharmaceuticals/*administration & dosage
Filgrastim/*administration & dosage
Polyethylene Glycols/*administration & dosage
Adolescent ; Adult ; Area Under Curve ; Biosimilar Pharmaceuticals/adverse effects ; Biosimilar Pharmaceuticals/pharmacokinetics ; Cross-Over Studies ; Female ; Filgrastim/adverse effects ; Filgrastim/pharmacokinetics ; Headache/chemically induced ; Humans ; Leukocyte Count ; Male ; Musculoskeletal Pain/chemically induced ; Neutrophils/drug effects ; Polyethylene Glycols/adverse effects ; Polyethylene Glycols/pharmacokinetics ; Therapeutic Equivalency ; Young Adult
Czasopismo naukowe
Tytuł :
Biosimilars: is interchangeability the proof of the pudding?
Autorzy :
Moore GT; Monash Health, Melbourne, VIC.; Monash University, Melbourne, VIC.
Keung C; Monash Health, Melbourne, VIC.
Pokaż więcej
Źródło :
The Medical journal of Australia [Med J Aust] 2021 Feb; Vol. 214 (3), pp. 124-125. Date of Electronic Publication: 2021 Jan 06.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Biosimilar Pharmaceuticals*
Inflammatory Bowel Diseases*
Australia ; Cohort Studies ; Humans ; Infliximab
Opinia redakcyjna
Tytuł :
Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
Autorzy :
Toosi R; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mahmoudi H; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Balighi K; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Teimourpour A; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.; Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Alaeen H; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Shaghaghi M; Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Hospital, Baltimore, MD, USA.
Abedini R; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Daneshpazhooh M; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
The Journal of dermatological treatment [J Dermatolog Treat] 2021 Feb; Vol. 32 (1), pp. 33-40. Date of Electronic Publication: 2019 May 28.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Biosimilar Pharmaceuticals/*therapeutic use
Pemphigus/*drug therapy
Adult ; Antineoplastic Agents, Immunological/adverse effects ; Biosimilar Pharmaceuticals/adverse effects ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Pemphigus/mortality ; Prednisolone/therapeutic use ; Prospective Studies ; Recurrence ; Remission Induction ; Rituximab/adverse effects ; Rituximab/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
An administrative fix for manufacturing process patent thickets.
Autorzy :
Rai AK; The Center for Innovation Policy, Duke University Law School, Durham, NC, USA. .
Price WN 2nd; University of Michigan Law School, Ann Arbor, MI, USA.; Centre for Advanced Studies in Biomedical Innovation Law, University of Copenhagen, Copenhagen, Denmark.
Pokaż więcej
Źródło :
Nature biotechnology [Nat Biotechnol] 2021 Jan; Vol. 39 (1), pp. 20-22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biosimilar Pharmaceuticals*
Biotechnology/*legislation & jurisprudence
Patents as Topic/*legislation & jurisprudence
Humans ; United States
Czasopismo naukowe
Tytuł :
Cryoglobulinemic vasculitis: having giant steps; but there are still unanswered questions.
Autorzy :
Karadag O; Department of Internal Medicine, Division of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey. .; Hacettepe University Vasculitis Research Centre, Ankara, Turkey. .
Duran E; Department of Internal Medicine, Division of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey.; Hacettepe University Vasculitis Research Centre, Ankara, Turkey.
Pokaż więcej
Źródło :
Internal and emergency medicine [Intern Emerg Med] 2021 Jan; Vol. 16 (1), pp. 33-35. Date of Electronic Publication: 2020 Sep 04.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Biosimilar Pharmaceuticals*
Cryoglobulinemia*/complications
Cryoglobulinemia*/diagnosis
Vasculitis*/diagnosis
Antibodies, Monoclonal, Murine-Derived ; Calcium Carbonate ; Humans ; Rituximab
Czasopismo naukowe
Tytuł :
Biosimilars in Inflammatory Bowel Disease.
Autorzy :
Buchner AM; Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Schneider Y
Lichtenstein GR
Pokaż więcej
Źródło :
The American journal of gastroenterology [Am J Gastroenterol] 2021 Jan 01; Vol. 116 (1), pp. 45-56.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Biosimilar Pharmaceuticals/*therapeutic use
Inflammatory Bowel Diseases/*drug therapy
Tumor Necrosis Factor Inhibitors/*therapeutic use
Adalimumab/economics ; Adalimumab/therapeutic use ; Biosimilar Pharmaceuticals/economics ; Drug Costs ; Drug Substitution ; Health Expenditures ; Health Services Accessibility ; Humans ; Infliximab/economics ; Infliximab/therapeutic use
Czasopismo naukowe
Tytuł :
Effect of a novel animal milk oligosaccharide biosimilar on macronutrient digestibility and gastrointestinal tolerance, fecal metabolites, and fecal microbiota of healthy adult cats.
Autorzy :
Oba PM; Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL.
Lee AH; Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL.
Vidal S; Gnubiotics Sciences SA, Epalinges, Switzerland.
Wyss R; Gnubiotics Sciences SA, Epalinges, Switzerland.
Miao Y; Gnubiotics Sciences SA, Epalinges, Switzerland.
Adesokan Y; Gnubiotics Sciences SA, Epalinges, Switzerland.
Swanson KS; Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL.; Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL.; Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL.
Pokaż więcej
Źródło :
Journal of animal science [J Anim Sci] 2021 Jan 01; Vol. 99 (1).
Typ publikacji :
Journal Article; Randomized Controlled Trial, Veterinary
MeSH Terms :
Biosimilar Pharmaceuticals*
Microbiota*
Animal Feed/analysis ; Animals ; Cats ; Diet/veterinary ; Digestion ; Feces ; Female ; Male ; Milk ; Nutrients ; Oligosaccharides
Czasopismo naukowe
Tytuł :
Evaluation of a novel animal milk oligosaccharide biosimilar: macronutrient digestibility and gastrointestinal tolerance, fecal metabolites, and fecal microbiota of healthy adult dogs and in vitro genotoxicity assays.
Autorzy :
Lee AH; Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL.
Vidal S; Gnubiotics Sciences SA, Epalinges, Switzerland.
Oba PM; Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL.
Wyss R; Gnubiotics Sciences SA, Epalinges, Switzerland.
Miao Y; Gnubiotics Sciences SA, Epalinges, Switzerland.
Adesokan Y; Gnubiotics Sciences SA, Epalinges, Switzerland.
Swanson KS; Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL.; Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL.; Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL.
Pokaż więcej
Źródło :
Journal of animal science [J Anim Sci] 2021 Jan 01; Vol. 99 (1).
Typ publikacji :
Journal Article
MeSH Terms :
Biosimilar Pharmaceuticals*
Microbiota*
Animal Feed/analysis ; Animals ; Diet/veterinary ; Digestion ; Dogs ; Feces ; Milk ; Nutrients ; Oligosaccharides
Czasopismo naukowe
Tytuł :
Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products.
Autorzy :
Mouslim MC; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: .
Trujillo AJ; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Alexander GC; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.
Segal JB; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, MD, USA; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Pokaż więcej
Źródło :
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2020 Dec; Vol. 23 (12), pp. 1599-1605. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Biosimilar Pharmaceuticals/*economics
Filgrastim/*economics
Health Expenditures/*statistics & numerical data
Biosimilar Pharmaceuticals/supply & distribution ; Biosimilar Pharmaceuticals/therapeutic use ; Cost Savings/statistics & numerical data ; Drug Costs/statistics & numerical data ; Female ; Filgrastim/therapeutic use ; Humans ; Insurance Claim Review ; Insurance, Health/economics ; Insurance, Health/statistics & numerical data ; Interrupted Time Series Analysis ; Longitudinal Studies ; Male ; Middle Aged ; United States
Czasopismo naukowe
Tytuł :
Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience.
Autorzy :
Barker J; St John's Institute of Dermatology King's College, London, UK.
Girolomoni G; Department of Medicine, University of Verona School of Medicine, Verona, Italy.
Egeberg A; Department of Dermatology and Allergy, Gentofte Hospital, Copenhagen, Denmark.
Goncalves J; Faculty of Pharmacy, iMed - Research Institute for Medicines, University of Lisbon, Lisbon, Portugal.
Pieper B; Biogen International GmbH, Baar, Switzerland.
Kang T; Samsung Bioepis Co., Ltd, Incheon, Republic of Korea.
Pokaż więcej
Źródło :
The Journal of dermatological treatment [J Dermatolog Treat] 2020 Dec; Vol. 31 (8), pp. 794-800. Date of Electronic Publication: 2019 May 16.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Biosimilar Pharmaceuticals/*therapeutic use
Psoriasis/*drug therapy
Tumor Necrosis Factor Inhibitors/*therapeutic use
Arthritis, Rheumatoid/drug therapy ; Biosimilar Pharmaceuticals/economics ; Biosimilar Pharmaceuticals/supply & distribution ; Cost Savings ; Drug Costs ; Health Services Accessibility/economics ; Humans ; Kaplan-Meier Estimate ; Tumor Necrosis Factor Inhibitors/economics ; Tumor Necrosis Factor Inhibitors/supply & distribution
Czasopismo naukowe
Tytuł :
Commentary - A comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars and Intended Copy Biologics in treating chemotherapy associated febrile neutropenia.
Autorzy :
Cornes PG; Comparative Outcomes Group, United Kingdom. Electronic address: .
Muenzberg M; Comparative Outcomes Group, United Kingdom.
Pokaż więcej
Źródło :
Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2020 Nov 01; Vol. 406, pp. 115202. Date of Electronic Publication: 2020 Aug 18.
Typ publikacji :
Journal Article
MeSH Terms :
Biosimilar Pharmaceuticals/*therapeutic use
Febrile Neutropenia/*drug therapy
Granulocyte Colony-Stimulating Factor/*therapeutic use
Antineoplastic Agents/adverse effects ; Biosimilar Pharmaceuticals/adverse effects ; Biosimilar Pharmaceuticals/pharmacokinetics ; Febrile Neutropenia/chemically induced ; Granulocyte Colony-Stimulating Factor/adverse effects ; Granulocyte Colony-Stimulating Factor/pharmacokinetics ; Humans ; Therapeutic Equivalency
Czasopismo naukowe
Tytuł :
Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar.
Autorzy :
Martínez-Feito A; Immuno-Rheumatology Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain. .; Immunology Unit, La Paz University Hospital, Madrid, Spain. .
Bravo-Gallego LY; Immunology Unit, La Paz University Hospital, Madrid, Spain.; Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ) and Center for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain.
Hernández-Breijo B; Immuno-Rheumatology Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.
Diez J; Biostatistics Section, La Paz University Hospital, Madrid, Spain.
García-Ramirez L; Unit of Inflammatory Bowel Disease, Gastroenterology Department. Innate Immunity Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.
Jaquotot M; Unit of Inflammatory Bowel Disease, Gastroenterology Department. Innate Immunity Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.
Plasencia-Rodríguez C; Immuno-Rheumatology Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.
Nozal P; Immunology Unit, La Paz University Hospital, Madrid, Spain.
Mezcua A; Immunology Unit, La Paz University Hospital, Madrid, Spain.
Martín-Arranz MD; Unit of Inflammatory Bowel Disease, Gastroenterology Department. Innate Immunity Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.
Pascual-Salcedo D; Immuno-Rheumatology Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 13; Vol. 10 (1), pp. 17099. Date of Electronic Publication: 2020 Oct 13.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*pharmacokinetics
Biosimilar Pharmaceuticals/*pharmacokinetics
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*pharmacokinetics
Adolescent ; Adult ; Antibodies, Monoclonal/blood ; Antibodies, Monoclonal/therapeutic use ; Biomarkers/blood ; Biosimilar Pharmaceuticals/blood ; Biosimilar Pharmaceuticals/therapeutic use ; Female ; Humans ; Inflammatory Bowel Diseases/blood ; Infliximab/blood ; Infliximab/therapeutic use ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Autorzy :
Bennett CL; College of Pharmacy, University of South Carolina, Columbia, SC, USA; WJB Dorn VA Medical Center, Columbia, SC, USA; Department of Comparative Medicine and Evidence Based Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: .
Schoen MW; Saint Louis University School of Medicine, Saint Louis, MO, USA; John Cochran VA Medical Center, Saint Louis, MO, USA.
Hoque S; College of Engineering and Computing, University of South Carolina, Columbia, SC, USA; WJB Dorn VA Medical Center, Columbia, SC, USA.
Witherspoon BJ; College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Aboulafia DM; Virginia Mason Medical Center, Seattle, WA, USA.
Hwang CS; Virginia Mason Medical Center, Seattle, WA, USA.
Ray P; College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Yarnold PR; College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Chen BK; The Arnold School of Public Health, University of South Carolina, Columbia, SC, USA; WJB Dorn VA Medical Center, Columbia, SC, USA.
Schooley B; College of Engineering and Computing, University of South Carolina, Columbia, SC, USA.
Taylor MA; School of Medicine, University of South Carolina, Columbia, SC, USA.
Wyatt MD; College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Hrushesky WJ; College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Yang YT; School of Nursing and Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Dec; Vol. 21 (12), pp. e575-e588.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
MeSH Terms :
Drug Approval*/legislation & jurisprudence
United States Food and Drug Administration*/legislation & jurisprudence
Antineoplastic Agents, Immunological/*therapeutic use
Biosimilar Pharmaceuticals/*therapeutic use
Hematinics/*therapeutic use
Neoplasms/*drug therapy
Antineoplastic Agents, Immunological/adverse effects ; Bevacizumab/therapeutic use ; Biosimilar Pharmaceuticals/adverse effects ; Drug Substitution ; Erythropoietin/analogs & derivatives ; Erythropoietin/therapeutic use ; Europe ; Filgrastim/therapeutic use ; Hematinics/adverse effects ; Humans ; Japan ; Neoplasms/immunology ; Neoplasms/mortality ; Patient Safety ; Policy Making ; Polyethylene Glycols/therapeutic use ; Risk Assessment ; Rituximab/therapeutic use ; Trastuzumab/therapeutic use ; Treatment Outcome ; United States
Czasopismo naukowe
Tytuł :
Revisiting same day administration of pegfilgrastim in the age of biosimilars: A review of literature.
Autorzy :
Gerberich AJ; Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA.
Attilio MR; Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA.
Svoboda A; Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2020 Dec; Vol. 26 (8), pp. 1970-1976. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Biosimilar Pharmaceuticals/*administration & dosage
Filgrastim/*administration & dosage
Neoplasms/*drug therapy
Polyethylene Glycols/*administration & dosage
Biosimilar Pharmaceuticals/therapeutic use ; Humans
Czasopismo naukowe
Tytuł :
Randomized Comparative Clinical Study of First Global Omalizumab Biosimilar with Innovator Product in Moderate to Severe Persistent Asthma.
Autorzy :
Apsangikar P; Head Medical Affairs, Reliance Life Sciences Pvt. Ltd., Mumbai, Maharashtra.
Ghadge P; Head Clinical Research, Reliance Life Sciences Pvt. Ltd., Mumbai, Maharashtra.
Naik M; Head Pharmacovigilance, Reliance Life Sciences Pvt. Ltd., Mumbai, Maharashtra.
Nair S; Divisional Medical Head, Reliance Life Sciences Pvt. Ltd., Mumbai, Maharashtra.
Pokaż więcej
Źródło :
The Journal of the Association of Physicians of India [J Assoc Physicians India] 2020 Dec; Vol. 68 (12), pp. 61-65.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Anti-Asthmatic Agents*/adverse effects
Asthma*/drug therapy
Biosimilar Pharmaceuticals*/therapeutic use
Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Humans ; Omalizumab/adverse effects ; Quality of Life ; Treatment Outcome
Czasopismo naukowe
Tytuł :
[Immunotherapies in the German healthcare system : Economic aspects of established antibodies and recently available therapies].
Autorzy :
Huppertz E; Im Sand 4, 56412, Niedererbach, Deutschland. .
Pokaż więcej
Transliterated Title :
Immuntherapien im deutschen Gesundheitswesen : Ökonomische Aspekte etablierter Antikörper und neuerer Therapien.
Źródło :
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz [Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz] 2020 Nov; Vol. 63 (11), pp. 1431-1441. Date of Electronic Publication: 2020 Oct 22.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Biosimilar Pharmaceuticals*/therapeutic use
Delivery of Health Care ; Germany ; Health Expenditures ; Immunotherapy ; National Health Programs
Czasopismo naukowe
Tytuł :
[Biosimilars in the European Union: current situation and challenges].
Autorzy :
Wolff-Holz E; Paul-Ehrlich-Institut (PEI), Paul-Ehrlich-Str. 51-56, 63225, Langen, Deutschland. .
Weise M; Bundesinstitut für Arzneimittel, (BfArM), Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Deutschland.
Pokaż więcej
Transliterated Title :
Biosimilars in der EU: Bestandsaufnahme und neue Herausforderungen.
Źródło :
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz [Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz] 2020 Nov; Vol. 63 (11), pp. 1365-1372. Date of Electronic Publication: 2020 Oct 09.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Biosimilar Pharmaceuticals*/therapeutic use
Antibodies, Monoclonal ; European Union ; Germany ; Humans
Czasopismo naukowe
Tytuł :
Comment to "Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease".
Autorzy :
Barreiro de Acosta M; IBD Unit. Gastroenterology Department. University Hospital of Santiago de Compostela, Spain. Electronic address: .
Katsanos KH; Division of Gastroenterology. Medical School and University Hospital of Ioannina, Greece.
Pokaż więcej
Źródło :
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2020 Nov; Vol. 52 (11), pp. 1302-1303. Date of Electronic Publication: 2020 Sep 08.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Biosimilar Pharmaceuticals*
Colitis*
Inflammatory Bowel Diseases*/drug therapy
Humans ; Infliximab ; Italy
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies